UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Jul. 31, 2026	Jul. 31, 2025
Income Statement [Abstract]
Revenue, Product and Service [Extensible List]	Service [Member]	Service [Member]
Oncology revenue	$ 15,232	$ 13,995
Costs and operating expenses:
Cost, Product and Service [Extensible List]	Service [Member]	Service [Member]
Cost of oncology revenue	$ 7,534	$ 7,995
Research and development	2,344	2,082
Sales and marketing	3,090	1,855
General and administrative	2,673	2,570
Loss on disposal of equipment	0	20
Total costs and operating expenses	15,641	14,522
Loss from operations	(409)	(527)
Other income (expense), net	(6)	75
Loss before provision for income taxes	(415)	(452)
Provision for income taxes	11	14
Net income (loss) attributable to Company's common shares	$ (426)	$ (466)
Net loss per common share outstanding
basic (in dollars per share)	$ (0.03)	$ (0.03)
Weighted average common shares outstanding
basic (in shares)	13,897,535	13,788,414